At present, there are many examples of overexpression and overactivation of STAT1 associated with cancer, and various strategies have been employed to develop STAT inhibitors, including interfering with SH2-mediated dimerization, DNA binding, or deactivation and inducing STAT degradation (28). This evidence concerns the gene STAT1 and cancer.